Patient-controlled intravenous analgesia with remifentanil in nulliparous subjects in labor

Basit Öğe Kaydı
dc.contributor.authorBalcıoğlu, Okan
dc.contributor.authorAkın, Şule
dc.contributor.authorDemir, Selim
dc.contributor.authorArıboğan, Anış
dc.date.accessioned2020-04-30T23:20:37Z
dc.date.available2020-04-30T23:20:37Z
dc.date.issued2007
dc.departmentDÜ, İşletme Fakültesien_US
dc.descriptionWOS: 000251666100001en_US
dc.descriptionPubMed: 18035955en_US
dc.description.abstractObjective: in this study we controlled the efficiency and safety of using remifentanil combined with two different supplementary background infusions for labor analgesia in nulliparous patients. Research design and methods: 60 subjects were allocated to two groups. After programming the patient-controlled analgesia device to deliver a fixed load and demand doses of intravenous remifentanil for all subjects, group r (n = 30) received a background infusion of remifentanil 0.1 mu g/kg/min and group R (n = 30) received a supplementary infusion of remifentanil 0.15 mu g/kg/min. Visual analogue scale for analgesia, hemodynamic parameters, sedation scales and fetal heart rates were recorded at the 5th, 10th, 20th and 30th min of the study and measurements continued every 15 min during 90 min of labor and delivery. Side effects, Apgar and satisfaction scores were obtained for every subject. Results: visual analogue scale scores of group R were significantly lower than those of group r throughout labor and delivery (p < 0.05). Hemodynamic parameters and fetal heart rates of the two groups were not different (p > 0.05). Most subjects were awake and only nausea was obtained (p > 0.05). The increase in the Apgar and satisfaction scores was not statistically significant (p > 0.05). Conclusion: it was determined that remifentanil with a 15-mu g demand dose and 0.15 mu g/kg/min supplementary continuous infusion is an effective choice for patient-controlled analgesia during labor in nulliparous subjects.en_US
dc.identifier.doi10.1517/14656566.8.18.3089en_US
dc.identifier.endpage3096en_US
dc.identifier.issn1465-6566
dc.identifier.issue18en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage3089en_US
dc.identifier.urihttps://doi.org/10.1517/14656566.8.18.3089
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4043
dc.identifier.volume8en_US
dc.identifier.wosWOS:000251666100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofExpert Opinion On Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectlaboren_US
dc.subjectnulliparousen_US
dc.subjectpatient-controlled analgesiaen_US
dc.subjectremifentanilen_US
dc.titlePatient-controlled intravenous analgesia with remifentanil in nulliparous subjects in laboren_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4043.pdf
Boyut:
215.46 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Öksüz Yayınlar Koleksiyonu